Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension Clinical Trial

Official title:

Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00423748
• Other study ID #: AMB-320
• Secondary ID: ARIES-1
• Status: Completed
• Phase: Phase 3
• First received: January 17, 2007
• Last updated: April 15, 2009
• Start date: December 2003
• Est. completion date: February 2006

Study information

• Verified date: April 2009
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Description:

Subjects in these randomized studies will receive one of two doses of ambrisentan or placebo. Inclusion is not based on a specified WHO functional classification. Rather, subjects with WHO Class I-IV symptoms are eligible if their 6-minute walk distance is 150-450 meters and they meet the study-specified hemodynamic criteria. Subjects with anorexigen or HIV infection related PAH are eligible but subjects with congenital heart disease and pediatric subjects are excluded. The study requires a historical cardiac catheterization and other diagnostic procedures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 186
• Est. completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or order

• Current diagnosis of either PPH orPAH secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit

• Right heart catheterization, completed prior to Screening Visit must meet pre-specified hemodynamic criteria

• Female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit

• Male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form

Exclusion Criteria:

• PAH due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea

• Portopulmonary hypertension

• Bosentan within four weeks prior to Screening

• Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks prior to Screening

• IV inotrope use within two weeks prior to Screening

• ALT or AST lab value that is greater than 1.5 times the upper limit of normal

• Pulmonary function tests not meeting pre-specified criteria

• Contraindication to treatment with an ERA

• History of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years

• Females who are pregnant or breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• ambrisentan

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.
Secondary	Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index; WHO Functional Classification; and the SF-36 Health Survey.
Secondary	Clinical worsening of PAH.
Secondary	Assessment of the safety and tolerability of the study drug.